In primary breast tumors from patients carrying BRCA1 mutations, it has been demonstrated that there is a significant increase in IGF‐I receptor levels compared with tumors from sporadic (nonfamilial) patients with BC [118]. The gene discussed is BRCA1; the disease is breast cancer.